Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma (MREO) Accounts Payables (2020 - 2025)

Mereo BioPharma (MREO) has disclosed Accounts Payables for 6 consecutive years, with $879000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Accounts Payables fell 49.71% to $879000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $879000.0, a 49.71% decrease, with the full-year FY2024 number at $2.4 million, up 4.01% from a year prior.
  • Accounts Payables was $879000.0 for Q3 2025 at Mereo BioPharma, down from $1.1 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $3.5 million in Q4 2022 to a low of $879000.0 in Q3 2025.
  • A 5-year average of $2.3 million and a median of $2.4 million in 2024 define the central range for Accounts Payables.
  • Biggest YoY gain for Accounts Payables was 19.1% in 2025; the steepest drop was 57.85% in 2025.
  • Mereo BioPharma's Accounts Payables stood at $3.4 million in 2021, then grew by 3.66% to $3.5 million in 2022, then crashed by 32.82% to $2.3 million in 2023, then grew by 4.01% to $2.4 million in 2024, then tumbled by 63.98% to $879000.0 in 2025.
  • Per Business Quant, the three most recent readings for MREO's Accounts Payables are $879000.0 (Q3 2025), $1.1 million (Q2 2025), and $2.9 million (Q1 2025).